National and Kapodistrian University of Athens
Νέες στρατηγικές επαγωγής ανοσολογικής ανοχής έναντι αυτοαντιγόνων μυελίνης για τη θεραπεία της σκλήρυνσης κατά πλάκας
Abstract
dc:descriptionAutoimmune diseases of the CNS, such as multiple sclerosis (MS), are the main cause of non-traumatic disability in young adults. Adaptive immunity in co-operation with innate immunity, not only overcome the immune privilege mechanisms that protect the CNS against foreign threats, but also peripheral immune tolerance mechanisms towards self, and trigger an immune response against the myelin sheath, that protects and insulates the neurons. This results in inflammation, demyelination, glial cell activation and problems in neural transmission that are responsible for neuronal deficits. Critical mediators of CNS demyelinating diseases are T cells, B cells and monocytes/macrophages, that are abundant in the CNS lesions. Approved therapies are only partially effective and are often associated with adverse effects, because of the general immunosuppression they induce. Therefore, there is a need for targeted therapies that more specifically target the cells responsible for myelin destruction, without affecting other immune responses. The goal of current research is the development of antigen-specific therapies for the treatment of autoimmune demyelination.Experimental autoimmune encephalomyelitis (EAE) is a valuable tool in developing such therapies, as it is the most widely used model of human autoimmune demyelinating diseases. EAE model shares some common immunological and pathophysiological mechanisms with MS, neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein associated disease (MOGAD). Myelin-specific Th1 and Th17 CD4+ cells are both necessary and sufficient to induce disease. Together with antigen-specific T cells, myeloid cells are key mediators of EAE, and the relative contribution of blood borne monocytes and tissue resident macrophages, in disease pathology and tissue recovery is the subject of current research. Previously we showed that oxidized mannan (OM) conjugated myelin autoantigens induce antigen-specific tolerance in EAE and protect mice from the clinical and histopathological signs of the disease. Our studies showed that tolerance is associated with reduced antigen-specific T cell proliferation, without involving other classical mechanisms of T cell tolerance, namely, clonal T cell deletion, the maturation of Th1 and Th17 cells, Th1/Th2 immune deviation, or the induction of Tregs in peripheral lymphoid organs. Further in vitro and in vivo studies showed that in addition to reduced antigen-specific proliferation, T cells also had produced less of the growth cytokine IL-2 and its receptor CD25, all features of T cell anergy. Nevertheless, the mechanism of anergy remained elusive.In this thesis we further investigated the therapeutic effects of OM conjugated MOG peptide 35-55 (OM-MOG) in EAE, to gain in depth insight into the mechanism of tolerance. CD4+ T cells from the spleens of OM-MOG vaccinated mice have an anergic phenotype, with high expression of CD44 and of folate receptor FR4, while exhibiting normal polyclonal responses, further showing that the tolerance is antigen-specific. Studies in humanized HLA-DR2b transgenic mice (DR2b.Ab°), that lack all murine MHC class II (MHCII) molecules and are susceptible to MOG35-55 induced EAE, showed that OM-MOG protects and treats the clinical and histopathological symptoms of EAE further supporting that tolerance is independent of MHCII type. The histopathological analysis of DR2b.Ab° mice spinal cords, showed that OM-MOG reduced inflammation, demyelination and neuronal damage. Further studies in C57BL/6 (Β6) mice showed the preservation of axonal integrity in spinal cord lesions and the increase in expression of genes associated with myelin (Mbp encoding myelin basic protein/MBP) and neuron recovery (Snap25 encoding synaptosomal-associated protein 25kDa/SNAP25) by OM-MOG. Immune tolerance by OM-MOG involved the rapid upregulation of PD-L1 and IL-10 production by myeloid cells, and gene markers of alternative activation (Ym1 encoding chitinase 3 like 3/CHI3L3) in secondary lymphoid organs, all features associated with a type 2 myeloid response. To investigate the cellular basis of tolerance, we further investigated the involvement of two immature myeloid cell populations with phenotype CD11b+Ly6G (Ly6G) and CD11b+Ly6Chi (Ly6Chi) in EAE, which along with T cells are necessary for the induction of EAE but also could directly mediate immune tolerance by their properties as myeloid derived suppressor cells (MDSC). Immature Ly6Chi cells that express the CCR2 receptor are known to be critical for the development of EAE. They migrate from the periphery to the CNS and mature within the CNS to exhibit their pathogenic roles. Therapeutic OM-MOG induces tolerance by prematurely inducing the maturation of Ly6ChiCCR2+ to Ly6ChiMHCII+PD-L1+ cells in the periphery, prior to their migration to the CNS, and thereby inhibiting spinal cord inflammation and demyelination in EAE mice. Soluble intradermal OM-MOG, drains directly to the skin draining lymph node to be sequestered by CD169+ subcapsular sinus macrophages, activates Ly6ChiCCR2+ monocytes to produce MHCII and PD-L1, preventing the trafficking of immune cells in the spinal cord and reversing the established lesions. To investigate the molecular basis, we also showed that PD-L1 is a critical mediator of immune tolerance, by using a neutralizing anti-PD-L1 antibody in vivo. Using the dendritic cell-specific Pdl1 knockout mice, we demonstrated that PD-L1 in non-dendritic cells is essential for the therapeutic effects of OM-MOG. These results show that the maturation of circulating Ly6ChiCCR2+ monocytes by OM-myelin peptides represents a novel mechanism of peripheral antigen-specific immune tolerance that reverses EAE, and a promising strategy for the design of therapies against autoimmune diseases with identified autoantigens.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Dagkonaki, Anastasia
- Δαγκωνάκη, Αναστασία
Subjects
dc:subject × 21- Σκλήρυνση κατά πλάκας
- Πειραματική αυτοάνοση εγκεφαλομυελίτιδα
- Ανοσολογική ανοχή
- Ανοσοθεραπεία
- Μυελοειδή κύτταρα
- Multiple sclerosis
- Experimental autoimmune encephalomyelitis
- Immune tolerance
- Immunotherapy
- Myeloid cells
- Βιολογία
- Φυσικές Επιστήμες
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανοσολογία
- Biological Sciences
- Natural Sciences
- Biology
- Basic Medicine
- Medical and Health Sciences
- Immunology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53350